Type 1 angiotensin II (AT 1 ) receptor has a critical role in the development of load-induced cardiac hypertrophy. Recently, we showed that mechanical stretching of cells activates the AT 1 receptor without the involvement of angiotensin II (AngII) and that this AngII-independent activation is inhibited by the inverse agonistic activity of the AT 1 receptor blocker (ARB), candesartan. Although the inverse agonist activity of ARBs has been studied in terms of their action on constitutively active AT 1 receptors, the structure-function relationship of the inverse agonism they exert against stretch-induced AT 1 receptor activation has not been fully elucidated. Assays evaluating c-fos gene expression and phosphorylated extracellular signal-regulated protein kinases (ERKs) have shown that olmesartan has strong inverse agonist activities against the constitutively active AT 1 receptor and the stretch-induced activation of AT 1 receptor, respectively. Ternary drug-receptor interactions, which occur between the hydroxyl group of olmesartan and Tyr 113 and between the carboxyl group of olmesartan and Lys 199 and His 256 , were essential for the potent inverse agonist action olmesartan exerts against stretch-induced ERK activation and the constitutive activity of the AT 1 -N111G mutant receptor. Furthermore, the inverse agonist activity olmesartan exerts against stretch-induced ERK activation requires an additional drug-receptor interaction involving the tetrazole group of olmesartan and Gln 257 of the AT 1 receptor. These results suggest that multivalent interactions between an inverse agonist and the AT 1 receptor are required to stabilize the receptor in an inactive conformation in response to the distinct processes that lead to an AngII-independent activation of the Keywords: angiotensin II; cardiac hypertrophy; G protein-coupled receptor; inverse agonist; mechanical stress
INTRODUCTION
The type 1 angiotensin II (AT 1 ) receptor is a member of the G proteincoupled receptor (GPCR) family and mediates most of the actions that angiotensin II (AngII) exerts on the cardiovascular system. 1 AT 1 receptor blockers (ARBs) are non-peptide compounds that selectively bind to the AT 1 receptor and inhibit AngII-induced receptor activation. At present, several ARBs are clinically available as a highly effective and well-tolerated class of drugs for the management of hypertension. In addition, clinical trials have indicated that ARBs provide cardiovascular protection that extends beyond blood pressure lowering. 2 Treatment with ARBs effectively prevents cardiac hypertrophy and improves cardiovascular outcomes in patients with hypertension. 2, 3 Structurally, most ARBs have a common biphenyl-tetrazole ring and unique side chains, which contribute to drug-specific differences in their pharmacokinetic and pharmacodynamic properties. 2, 4 These structural and pharmacological differences among ARBs may have an impact on long-term cardiovascular outcomes, although the clinical significance of these differences remains to be determined in large-scale trials.
Recent studies have shown that most GPCRs, including the AT 1 receptor, show spontaneous activity even in the absence of an agonist. 5 The AT 1 receptor is also activated by the mechanical stress of cellular stretching without the involvement of AngII. 6, 7 A ligand capable of suppressing the agonist-independent activities of a receptor is defined as an inverse agonist. 5, 8 We have previously reported that pressure overload induces cardiac hypertrophy in angiotensinogen-deficient mice as well as in wild-type (WT) mice and that hypertrophy is significantly attenuated by the inverse agonist, candesartan. 6 Therefore, the inverse agonist activities of ARBs have potential therapeutic benefits, at least in the prevention of load-induced cardiac hypertro-phy. The structural features that are required for the inverse agonist properties of some ARBs have been studied in constitutively active AT 1 receptors that have an Asn 111 mutation. For example, the ternary interactions between the hydroxyl group of the imidazole ring and Tyr 113 of the AT 1 receptor and between the carboxyl group and Lys 199 and His 256 of the AT 1 receptor were required for the inverse agonist activity that olmesartan exerts on GTPase-stimulating activity in a constitutively active AT 1 -N111G mutant containing an Asn 111 to Gly mutation. 9 However, studies using substituted cysteine accessibility mapping (SCAM) showed that conformation of the AT 1 p-ERKs during stretch-induced activation is quite different from that of the AT 1 -N111G receptor. 7, 10 Transmembrane domain 7 (TM7) of the AT 1 receptor undergoes a counterclockwise rotation and a shift toward the ligand-binding pocket in response to mechanical stretch, 7 but it shifts away from the ligand-binding pocket in the AT 1 -N111G receptor. 10 In this study, we show that, as an inverse agonist, olmesartan strongly inhibits the stretch-induced activation of the AT 1 receptor, as well as the constitutive activity of the AT 1 -N111G receptor. In addition to the ternary interactions involving the hydroxyl group and the carboxyl group of the imidazole ring of olmesartan, a specific drugreceptor interaction between the tetrazole group of olmesartan and Gln 257 of the AT 1 receptor is also important for the potent inverse agonist activity olmesartan exerts against stretch-induced AT 1 receptor activation. These results provide new insights into the structurefunction relationship of AT 1 receptor inverse agonists.
METHODS Materials
Olmesartan and its derivatives (R-88145, R-90929 and R-239470) were synthesized at the Research Laboratories of Daiichi Sankyo (Tokyo, Japan). The chemical structures of these compounds are shown in Figures 1a and 6b . AngII was purchased from Sigma-Aldrich (St Louis, MO, USA).
Cell culture and transfection
Cardiomyocytes obtained from ventricles of 1-day-old Wistar rats were plated at a field density of 1Â10 5 Inverse agonist activity of olmesartan Y Qin et al dishes. 6 Cardiomyocytes and HEK293 cells were cultured in DMEM supplemented with 10% fetal bovine serum and nutrient-starved under serum-free conditions for 48 h before AngII or stretch stimulation. The expression vector for AT 1 -WT and AT 1 -mutant receptors 9 was transfected using FuGENE 6 Transfection Reagent (Roche Diagnostics, Basel, Switzerland) according to the manufacturer's instructions. 7 
Western blot analysis
Total cellular proteins (20 mg) were fractionated by SDS-PAGE and transferred to Hybond membranes (GE Healthcare, Piscataway, NJ, USA). The blotted membranes were incubated with a polyclonal antibody recognizing phosphoextracellular signal-regulated protein kinase 1/2 (ERK1/2) (Cell Signaling, Beverly, MA, USA) or ERK1/2 (Zymed Laboratories, South San Francisco, CA, USA). Horseradish peroxidase-conjugated anti-rabbit IgG (immunoglobulin G) antibody was used as secondary antibody, and signals were detected using the ECL detection kit (GE Healthcare).
RNA extraction and northern blot analysis
Total RNA was isolated from AT 1 receptor-transfected COS7 cells using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions, and 20 mg of total RNA was hybridized with a cDNA probe for c-fos.
Luciferase assay
The c-fos luciferase reporter plasmid, with or without the expression vector for the AT 1 -WT or AT 1 -N111G receptor, was transfected using FuGENE 6 Transfection Regent (Roche Diagnostics) according to the manufacturer's instructions. pRL-SV40 (Promega, Madison, WI, USA) was co-transfected as an internal control. Luciferase activity was measured 24 h after transfection using the Dual-Luciferase Reporter Assay System (Promega). Experiments were repeated at least in triplicate, and representative data are shown. The c-fos luciferase reporter plasmid was a generous gift from Dr M Tsuda (Toyama Medical and Pharmaceutical University, Toyama, Japan).
Statistical analysis
Statistical analyses comparing three or more independent experiments were carried out using one-way ANOVA (analysis of variance) and Dunnett's t-test. P-values o0.05 were considered statistically significant.
RESULTS

Inhibitory effects of olmesartan and its derivative compounds on AngII-induced activation of the AT 1 receptor
We first determined the inhibitory effects of olmesartan and its derivative compounds, namely R-239470 and R-90929 (Figure 1a ), on AngII-induced ERK activation. As previously reported, stimulation with AngII for 8 min induced a significant increase in the phosphorylation level of ERKs in HEK293 cells expressing the AT 1 receptor (Figure 1b ). 7 Pretreatment with 10 À7 M olmesartan strongly inhibited ERK activation induced even by 10 À6 M AngII. The concentrationresponse curve of AngII-induced ERK activation in the presence of olmesartan (10 À6 to 10 À9 M) showed that olmesartan produced an insurmountable inhibitory effect on the AT 1 receptor, because it decreased the maximal response to AngII (Figure 1b) . In contrast, R-239470 and R-90929, which lack the carboxyl or hydroxyl group possessed by olmesartan, respectively, showed surmountable inhibitory effects and led to a rightward shift of the concentration-response curve rather than a decrease in maximal response (Figure 1b) . We have further confirmed that these side-chain structures are crucial for the insurmountable inhibitory effect olmesartan exerts on AngII-induced c-fos gene expression. Stimulation with 10 À6 M AngII significantly increased the expression level of c-fos mRNA, which was suppressed significantly by pretreatment with olmesartan but only partially by pretreatment with R-239470 or R-90929 (Figure 1c) . Similarly, stimulation with 10 À6 M AngII for 24 h induced a 12-fold increase in c-fos promoter activity, which was suppressed significantly by pretreatment with olmesartan but only partially suppressed by pretreatment with R-239470 or R-90929 (Figure 1d) .
Collectively, these results suggest that the carboxyl group and the hydroxyl group on the imidazole ring of olmesartan are required for Inhibitory effects of olmesartan and its derivative compounds on stretch-induced ERK activation A recent study showed that olmesartan suppresses the basal production of inositol phosphate (IP) in cells expressing WT AT 1 receptor (AT 1 -WT) and a constitutively active mutant AT 1 receptor (AT 1 -N111G). 9 We also found that basal c-fos promoter activity was suppressed by olmesartan in HEK293 cells expressing AT 1 -N111G (Figure 2 ). The inhibitory effect of olmesartan on basal c-fos promoter activity was significantly stronger than that of losartan ( Figure 3) . Olmesartan is therefore defined as an inverse agonist of the AT 1 receptor because it decreases the basal activity level of the receptor in the absence of the agonist. 
Inverse agonist activity of olmesartan Y Qin et al
We recently reported that mechanical stress activates the AT 1 receptor independently of AngII and that this AngII-independent activation of AT 1 receptor is inhibited by the inverse agonist, candesartan. 6 Therefore, we next examined the inhibitory effects of olmesartan on stretch-induced ERK activation in cardiomyocytes cultured from neonatal rats. We found that the stretch-induced phosphorylation of ERKs in cultured cardiomyocytes was largely dependent on the direct activation of AT 1 receptor and that AngII, even if secreted from cardiomyocytes, had only a marginal role in the stretch-induced activation of ERKs. 6 We found that the activation of ERKs in response to mechanical stretch was significantly attenuated by a pretreatment with 10 À7 M olmesartan (Figure 4a) . Furthermore, to exclude the effect of secreted AngII on stretch-induced ERK activation, we imposed stretch stimulation on HEK293 cells that showed no detectable expression of angiotensinogen. 6 Neither stimulation with AngII nor mechanical stretch activated ERKs in HEK293 cells, but mechanical stretching did activate ERKs in these cells when the AT 1 receptor was overexpressed 6 (Figure 4b ). Similar to the results in cardiomyocytes, pretreatment with olmesartan significantly inhibited stretch-induced ERK activation in HEK293 cells expressing the AT 1 receptor (HEK293-AT 1 cells) (Figure 4b ). Furthermore, the inhibitory effect of olmesartan on stretch-induced ERK activation was significantly stronger than that of losartan ( Figure 5 ). These results suggest that olmesartan, as a potent inverse agonist, strongly suppresses stretch-induced ERK activation, as well as the basal activity of the AT 1 receptor.
We further examined the inhibitory effects of R-239470 and R-90929 on stretch-induced ERK activation, both in cardiomyocytes and in HEK293-AT 1 cells. As shown in Figure 4 , 10 À7 M R-239470 or R-90929 could not inhibit ERK activation induced either by 10 À7 M AngII or by mechanical stretch, although 10 À7 M olmesartan inhibited ERK activation. Interestingly, AngII-induced ERK activation was inhibited by 10 À5 M R-239470 and 10 À6 M R-90929, but stretchinduced ERK activation was not inhibited by the same concentrations of these compounds (Figure 4) . These results suggest that the carboxyl and the hydroxyl groups present in olmesartan are responsible for the potent inverse agonist activity olmesartan exerts against stretch-induced ERK activation. Similar to the results of experiments evaluating stretch-induced ERK activation, 10 À5 M R-239470 and 10 À6 M R-90929 failed to suppress basal c-fos promoter activity in HEK293 cells expressing AT 1 -N111G (Figure 2 ).
Inhibitory effects of olmesartan on stretch-induced ERK activation in mutated AT 1 receptors Structure-function analyses have shown that ternary interactions between the hydroxyl group of olmesartan and Tyr 113 of the AT 1 receptor and between the carboxyl group of olmesartan and Lys 199 and His 256 of the AT 1 receptor are essential for the inverse agonist activity that olmesartan exerts on basal IP production in both AT 1 -WT and AT 1 -N111G receptors. 9 The tetrazole group of olmesartan also interacts with Gln 257 of the AT 1 receptor, but its binding is not required to reduce the basal activity level of the AT 1 receptor. 9 We first examined the effect of olmesartan on stretch-induced ERK activation in HEK293 cells overexpressing AT 1 -WT or an AT 1 mutant receptor harboring one of the following mutations: Y113F, K199Q, H256A or Q257A. As shown in Figure 6a , mechanical stretch-induced phosphorylation of ERKs occurred in AT 1 -Y113F, AT 1 -K199Q, AT 1 -H256A and AT 1 -Q257A cells in degrees equivalent to AT 1 -WT cells. Interestingly, the inhibitory effects of olmesartan on stretch-induced ERK activation were abolished in cells expressing AT 1 -Y113F, AT 1 -K199Q, AT 1 -H256A or AT 1 -Q257A (Figure 6a ). These results suggest that the interactions between olmesartan and Gln 257 , Tyr 113 , Lys 199 and His 256 are required for the potent inverse agonism olmesartan exerts on stretch-induced activation of the AT 1 receptor.
As the tetrazole ring of olmesartan interacts with Gln 257 of the AT 1 receptor, 9 we next examined the inhibitory effect that R-88145 (in which the tetrazole group was replaced with a carboxyl group, Figure 6b ) had on stretch-induced ERK activation in HEK293 cells overexpressing AT 1 -WT. Although 10 À7 M R-88145 did not inhibit ERK activation induced by 10 À7 M AngII, 10 À5 M R-88145 could inhibit ERK activation to an extent equivalent to 10 À7 M olmesartan (Figure 6c ). However, stretch-induced ERK activation was not significantly inhibited by 10 À5 M R-88145 (Figure 6c ). These results suggest that the interaction between the tetrazole group of olmesartan and Gln 257 of the AT 1 receptor is also responsible for the potent inverse agonist activity olmesartan exerts against stretch-induced ERK activation.
DISCUSSION
The ARBs share a common mode of action, namely they block AngIImediated responses, but the antihypertensive potency of ARBs differs by drug. 2, 4 Indeed, the pharmacokinetics of ARBs in human bodies, specifically factors such as bioavailability, half-life duration and route of elimination, differ considerably between different ARBs. These different degrees of efficacy possessed by ARBs are based on differences in their chemical structures, which determine their unique pharmacological properties. Insurmountable antagonism is one of the pharmacological parameters that is relevant to antihypertensive efficacy. 11 Insurmountable antagonism reflects tight binding and a slow dissociation of the drug-receptor complex. ARBs with insurmountable Figure 5 Comparison of the inverse agonist activities of olmesartan and losartan against stretch-induced ERK activation. HEK293-AT 1 cells were stimulated by mechanical stretch, and the activation of extracellular signalregulated protein kinase (ERKs) was determined. The inhibitory effect of 10 À7 M olmesartan on stretch-induced ERK activation was much stronger than that of 10 À7 M losartan. *Po0.01 vs. that of losartan. AT 1 , angiotensin II type 1.
Inverse agonist activity of olmesartan Y Qin et al antagonist properties suppress maximal AngII-induced responses. 11 Recently, it was reported that olmesartan showed a higher degree of insurmountable antagonism than did telmisartan against AngIIinduced IP accumulation in CHO-K1 cells expressing the AT 1 receptor. 12 In this study, we showed that olmesartan shows insurmountable antagonist activity against the AT 1 receptor and that the carboxyl and hydroxyl groups on the imidazole ring are required for the insurmountable inhibition of AngII-induced ERK activation and c-fos gene expression (Figure 1) . The unique side-chain structure olmesartan possesses (its carboxyl group and hydroxyl group) contributes to its specific receptor-binding activity. These drug-receptor interactions cooperate to stabilize the receptor in an inactive conformation and thereby confer inverse agonism against the basal expression of the c-fos gene (Figure 2 ) and the basal production of IP 9 in cells expressing the AT 1 -N111G receptor, as well as insurmountable antagonism. The inverse agonist activities that ARBs exert against the constitutive activity of the AT 1 receptor could be an important pharmacological parameter that may be relevant to their efficacy at blood pressure lowering and in preventing end-organ damage. Although it remains unclear whether the subtle constitutive activity of the native AT 1 receptor has a pathophysiological role, the enhancement of its constitutive activity olmesartan Inverse agonist activity of olmesartan Y Qin et al through upregulation of receptor expression may promote cardiovascular remodeling. Indeed, the expression level of the AT 1 receptor in vascular cells is upregulated by low-density lipoprotein cholesterol, 13 insulin, 14 glucose, 15 progesterone 16 and inflammatory cytokines, such as interleukin-1a or interleukin-6. 17, 18 Analyses of the binding affinity of olmesartan for mutant AT 1 receptors as well as molecular modeling analyses indicated that the ternary interactions between the hydroxyl group and Tyr 113 and between the carboxyl group and Lys 199 and His 256 are critical to the inverse agonist properties of olmesartan, but that the interaction between the tetrazole group and Gln 257 is dispensable. 9 Interestingly, differential interactions between valsartan and Ser 105 , and between Ser 109 and Lys 199 , are crucial for producing inverse agonism. 19 It has therefore been proposed that ARBs may bind to the AT 1 receptor primarily by docking at Lys 199 and subsequently through a distinct combination of drug-receptor interactions in a drug-specific manner. 19 According to this model, the spatial pattern of drug-receptor contact points will determine the potency of the inverse agonist activity of a given ARB.
We recently showed that mechanical stretching of cells induces a counterclockwise rotation and a shift of TM7 of the AT 1 receptor toward the ligand-binding pocket. 7 However, TM7 shifts away from the ligand-binding pocket in the AT 1 -N111G receptor, 10 implying that the conformation of AT 1 receptor during stretch-induced activation is different from that of the constitutively active AT 1 receptor. In general, GPCRs are structurally flexible and unstable, and multiple conformational states exist during the GPCR activation process. [20] [21] [22] In this study, we showed that, aside from the ternary drug-receptor interactions involving the hydroxyl and carboxyl groups of olmesartan, an additional interaction between the tetrazole group of olmesartan and Gln 257 of the AT 1 receptor is required for its potent inverse agonism against stretch-induced AT 1 receptor activation (Figures 4 and 6) . Each of the quaternary interactions involving the hydroxyl group, carboxyl group and tetrazole group contributes to a tight drugreceptor binding, 9 but is not sufficient enough to produce a potent inverse agonism against stretch-induced AT 1 receptor activation. Thus, the quaternary drug-receptor interactions work together to stabilize the receptor in an inactive conformation, even under conditions in which mechanical stretching occurs.
With regard to candesartan, the carboxyl group on the benzimidazole ring is responsible for its inverse agonism and leads to the suppression of both the constitutive activity and the mechanical stress-induced activation of the AT 1 receptor. 7 The SCAM studies showed that the binding of the carboxyl group of candesartan to Gln 257 of TM6 and Thr 287 of TM7 forcibly induces a clockwise rotation of TM6 and TM7, and leads to the stabilization of the AT 1 receptor in an inactive conformation. 7 At present, it remains unclear how the helical movement of TM7 induced by mechanical stretch is affected by the presence of olmesartan. According to molecular modeling, Thr 287 of TM7 is located in a position that would allow it to form a hydrogen bond with His 256 of TM6. 9 We assume that the helical movements of TM6 and TM7 are coupled and that TM7 may be restricted in motion when TM6 is rigidly bound to olmesartan through the dual interactions between the carboxyl group and His 256 and between the tetrazole group of olmesartan and Gln 257 .
Our study shows that olmesartan strongly inhibits both AngIIdependent and AngII-independent activation of the AT 1 receptor. Ternary drug-receptor interactions between the hydroxyl group and Tyr 113 and between the carboxyl group and Lys 199 and His 256 are crucial for olmesartan's inverse agonist activity against the constitutive activity of an AT 1 mutant receptor, AT 1 -N111G. In addition, a drugreceptor interaction between the tetrazole group of olmesartan and Gln 257 of the AT 1 receptor is required for potent inverse agonism against stretch-induced AT 1 receptor activation. These results suggest that multivalent drug-receptor interactions cooperate in combination to stabilize the receptor in an inactive conformation according to the distinct processes of receptor activation. The inverse agonist activity of ARBs has therapeutic benefits in the prevention of load-induced cardiac hypertrophy, 5 and thus has the potential to affect long-term outcomes in patients with hypertension. Elucidation of the molecular basis for the inverse agonist activity of ARBs in relation to their chemical structure will help to categorize ARBs according to their individual efficacies in receptor inactivation and will also help researchers to develop novel ARBs with superb efficacy in terms of blood pressure lowering and end-organ protection.
